Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
It further explores the potential of natural metabolic modulators in improving the tumor immune microenvironment and enhancing immunotherapy sensitivity
Structure's GLP-1 Pill Could Be Big, But Trial Results Will Confirm Structure Therapeutics Today GPCR Structure Therapeutics $49.12 -1.68 (-3.31%) As of 07/24/2026 04:00 PM Eastern 52-Week Range $15.80 $94.90 Price Target $110.55 Shares of Structure Therapeutics NASDAQ: GPCR have far outperformed both of the companies above in the last year, rising by over 150% during that time as investors have grown enthusiastic about aleniglipron, the firm's GLP-1 agonist candidate
United States America 117 (52), 3320433215
Joshua Rothman Grocery Shopping in the Age of Explosive Diarrhea The cyclospora outbreak lays bare our underfunded and overwhelmed public-health system
US$ 23.76
US$ 22.41
US$ 29.75
US$ 27.40
US$ 20.87
US$ 22.82
US$ 26.46
